TARRYTOWN, N.Y. - A COVID-19 antibody cocktail developed by U.S. drugmaker Regeneron offered strong protection against symptomatic infection when given to people living with someone else infected with the virus, the company said.Regeneron on Monday shared clinical trial results, which found that its REGEN-COV treatment reduced the overall risk of developing symptomatic COVID-19 by 81%, compared to those who received a placebo.In November, the drug received an emergency use authorization from the U.S.
Food and Drug Administration to treat mild-to-moderate COVID-19 patients. The new findings suggest the treatment could offer another form of protection against the virus for those who have not received a vaccination.